Login to Your Account

FDA stalls I.V. drug, asks to see more from Scynexis

By Randy Osborne
Staff Writer

Friday, March 3, 2017

In a second-quarter meeting with the FDA, Scynexis Inc. will be talking about three mild to moderate thrombotic events in healthy phase I volunteers.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription